[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PT2187958T - Vacina atenuada de erliquiose - Google Patents

Vacina atenuada de erliquiose

Info

Publication number
PT2187958T
PT2187958T PT87898763T PT08789876T PT2187958T PT 2187958 T PT2187958 T PT 2187958T PT 87898763 T PT87898763 T PT 87898763T PT 08789876 T PT08789876 T PT 08789876T PT 2187958 T PT2187958 T PT 2187958T
Authority
PT
Portugal
Prior art keywords
attenuated
ehrlichiosis
vaccine
ehrlichiosis vaccine
attenuated ehrlichiosis
Prior art date
Application number
PT87898763T
Other languages
English (en)
Inventor
Harrus Shimon
Baneth Gad
Original Assignee
Yissum Res Dev Company Of The Hebrew Univ Of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Company Of The Hebrew Univ Of Jerusalem filed Critical Yissum Res Dev Company Of The Hebrew Univ Of Jerusalem
Publication of PT2187958T publication Critical patent/PT2187958T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0233—Rickettsiales, e.g. Anaplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT87898763T 2007-09-11 2008-09-11 Vacina atenuada de erliquiose PT2187958T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97127107P 2007-09-11 2007-09-11

Publications (1)

Publication Number Publication Date
PT2187958T true PT2187958T (pt) 2017-03-17

Family

ID=40030309

Family Applications (1)

Application Number Title Priority Date Filing Date
PT87898763T PT2187958T (pt) 2007-09-11 2008-09-11 Vacina atenuada de erliquiose

Country Status (5)

Country Link
US (2) US8361480B2 (pt)
EP (1) EP2187958B1 (pt)
ES (1) ES2618842T3 (pt)
PT (1) PT2187958T (pt)
WO (1) WO2009034575A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013000045A (es) * 2010-07-02 2013-02-15 Univ Louisiana State Vacuna contra ehrlichia canis.
EP2433646A1 (en) * 2010-09-22 2012-03-28 Intervet International BV Vaccine against Ehrlichia canis and associated methods
US9580758B2 (en) 2013-11-12 2017-02-28 Luc Montagnier System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
US10335476B2 (en) 2014-10-21 2019-07-02 The Board Of Regents Of The University Of Texas System Vaccine to protect against Ehrlichia infection
US20180021421A1 (en) 2015-01-19 2018-01-25 Kansas State University Research Foundation Attenuated vaccines to protect against tick-borne ehrlichia species infections
CA3070102A1 (en) * 2017-07-31 2019-02-07 Kansas State University Research Foundation Vaccines against tick-borne diseases
EP3459561A1 (en) * 2017-09-21 2019-03-27 Centre de Cooperation Internationale en Recherche Agronomique pour le Developpement Live attenuated bacterial strain and its use as a vaccine
US10183073B1 (en) * 2017-09-29 2019-01-22 Hyper Light Technologies, Llc Method of making a vaccine
US10479988B2 (en) 2017-09-29 2019-11-19 Lumagenics, Llc Method of making a vaccine
BR112021001420A2 (pt) 2018-07-27 2021-05-04 Research Development Foundation polipeptídeos imunogênicos quiméricos

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US5047540A (en) 1987-12-17 1991-09-10 Shionogi & Co., Ltd. Lipid derivatives
US5192679A (en) 1990-05-03 1993-03-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Growing ehrlichia species in a continuous cell line
US6653128B2 (en) 1996-10-17 2003-11-25 University Of Florida Nucleic acid vaccines against rickettsial diseases and methods of use
US6306394B1 (en) 1997-04-25 2001-10-23 Aquila Biopharmaceuticals Inc. Nucleic acids, proteins, and methods of use of granulocytic ehrlichia
US6043085A (en) 1998-08-27 2000-03-28 Research Development Foundation Ehrlichia canis 120-kDa immunodominant antigenic protein and gene
US6458942B1 (en) 1998-11-30 2002-10-01 Research Development Foundation 28-kDa immunoreactive protein gene of Ehrlichia canis and uses thereof
US6392023B1 (en) 1999-03-03 2002-05-21 Research Development Foundation Homologous 28-kilodalton immunodominant protein genes of Ehrlicha canis and uses thereof
US7335754B2 (en) * 1999-07-21 2008-02-26 Cornell Research Foundation, Inc. Ehrlichia canis genes and vaccines
US6432649B1 (en) 2000-08-25 2002-08-13 The Ohio State University Research Foundation Methods for detecting Ehrlichia canis and Ehrlichia chaffeensis in vertebrate and invertebrate hosts
WO2003038061A2 (en) * 2001-11-01 2003-05-08 Research Development Foundation Ehrlichia disulfide bond formation proteins and uses thereof
AU2003290575B2 (en) 2002-11-04 2009-10-29 Research Development Foundation P153 and P156 antigens for the immunodiagnosis of canine and human ehrlichioses and uses thereof
US20050202046A1 (en) 2004-03-11 2005-09-15 Wyeth Canine vaccine for protection against ehrlichiosis
AU2006231473B2 (en) 2005-04-04 2012-01-12 Idexx Laboratories, Inc. Ehrlichia canis DIVA (differentiate infected from vaccinated animals)

Also Published As

Publication number Publication date
US8361480B2 (en) 2013-01-29
US20130122041A1 (en) 2013-05-16
ES2618842T3 (es) 2017-06-22
EP2187958A1 (en) 2010-05-26
US20100239613A1 (en) 2010-09-23
EP2187958B1 (en) 2016-12-21
WO2009034575A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
IL199663A0 (en) Vaccine
IL201782A0 (en) Vaccine
PT2187958T (pt) Vacina atenuada de erliquiose
GB0717911D0 (en) Vaccine
HRP20151124T1 (en) Vaccine
GB0700135D0 (en) Vaccine
ZA201004303B (en) Vaccine
GB0711858D0 (en) Vaccine
GB0822001D0 (en) Vaccine
GB0810710D0 (en) Vaccine
GB0816284D0 (en) Vaccine
GB0816447D0 (en) Vaccine
GB0710538D0 (en) Vaccine
ZA201003851B (en) Vaccine
EP2337847A4 (en) ADJUVANTS FOR VACCINES
IL204404A (en) Weakened fever vaccine
GB0709373D0 (en) BCG-based anti-atheroma vaccine
GB0712420D0 (en) Vaccine
GB0706825D0 (en) Vaccine
GB0712428D0 (en) Vaccine
GB0711357D0 (en) Vaccine
GB0713188D0 (en) Vaccine
GB0725121D0 (en) Vaccine
GB0725107D0 (en) Vaccine
GB0706540D0 (en) Anti-atheroma vaccine